Alcohol-related DisordersPhase 3NCT00444418
Medication and Counseling for Controlled Drinking (Project SMART)
A Phase 3 study testing Naltrexone and Brief Behavioral Compliance Enhancement Therapy in people with Alcohol-related Disorders and Alcohol Drinking, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA) at 1 site in United States.
Trial summary
The purpose of this study is to study the effectiveness of medication and specialized psychotherapy in helping gay and bisexual men who do not want to quit drinking learn how to reduce their drinking to healthier levels. More information on the study is available at www.projectsmartnyc.org. Read more about this study
- Who is it for?
- Ages 18 to 65 years, men only
- Conditions the study is for
- Alcohol-related Disorders, Alcohol Drinking, Alcoholism
- What is being tested?
- Naltrexone and Brief Behavioral Compliance Enhancement Therapy
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2006to Jun 2010
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males 18-65 years old
- Currently sexually active with other men
- Report drinking at levels substantially in excess of established guidelines for non-hazardous drinking
- Willing to reduce drinking to non-hazardous levels
- English literate (8th grade level)
Who cannot join
- Current physical disease or condition making participant inappropriate for a medication trial, including total bilirubin elevation >110%, AST or ALT elevations >300%.
- History of serious psychiatric illness (psychotic disorder, bipolar disorder, or psychiatric illness requiring hospitalization), current psychiatric illness (such as major depression or post-traumatic stress disorder) that requires treatment but that is currently untreated, or serious risk of suicidal or violent behavior
- Recent (past three months) initiation of psychotropic medication or psychotherapy, or recent change in psychotropic medication treatment
- Current DSM-IV diagnosis of drug (other than nicotine) dependence, or lifetime diagnosis of opioid dependence
- DSM-IV alcohol dependence diagnosis judged clinically severe, history or present evidence of significant alcohol withdrawal symptoms, or recurrent use of alcohol to alleviate withdrawal
- Regular use of opioids in the past month
Show all 9Show fewer
- History of hypersensitivity to NTX
- Considered by study physician not to be suitable for receipt of an investigational drug
- Likely to require treatment with opiate pain medication during the course of the study
Trial locations and contacts
1 site in 1 country.
United States1 site
Research Foundation for Mental Hygiene, Columbia Addiction Services and Psychotherapy Intervention Research, 3 Columbus Circle, Suite 1404
New York, New York, 10019
About this study
Official title: Naltrexone and CBT for Problem-drinking MSM
The purpose of this study is to study the effectiveness of medication and specialized psychotherapy in helping gay and bisexual men who do not want to quit drinking learn how to reduce their drinking to healthier levels. More information on the study is available at www.projectsmartnyc.org.
Read the detailed description
Problem drinking gay and bisexual men who try to quit drinking are at risk for relapse to heavy or problematic drinking because their social lives and social outlets are often strongly associated with alcohol. These men are most receptive to interventions focused on moderation of drinking rather than abstinence. However moderation-oriented cognitive-behavior therapy (CBT) and naltrexone (NTX) are both well established treatments for problem drinkers who wish to moderate, rather than stop, drinking. Research suggests that combining these treatments may enhance their efficacy.
This study combines moderation-oriented CBT with NTX in the treatment of problem drinking gay and bisexual men, who do not wish to abstain from alcohol, to evaluate their efficacy alone and in combination. We also propose to utilize new data collection technology, Interactive Voice Response, to collect data on daily relations among drinking, sexual behavior and psychological variables thought to mediate treatment response. Our objectives are to evaluate the efficacy of 12 weeks of randomly assigned treatment, with 100 mg of NTX or placebo, combined with brief supportive therapy or modified, behavioral self-control therapy specifically tailored to gay/bisexual men; to evaluate conditional relationships between heavy drinking and likelihood of HIV risk behavior; and to evaluate daily associations among mood, craving, self-efficacy, motivation, and drinking. Assessments will include baseline, 3, 6, \& 9 month follow-up. A substudy of the treatment trial will be conducted to collect and bank samples from blood for research aimed at associating naturally occurring differences in DNA with patient response to NTX, and with potential mediational mechanisms of action of NTX. Information gathered on genes or gene products may be used in conjunction with data on clinical and psychological factors obtained as part of the clinical trial to evaluate relationships among genetic variants, drug effects, and mechanisms of treatment response. Patients will be asked to give a blood sample at Week 0 of the clinical trial for the purpose of carrying out genetic research.
- Conditions
- Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
- Being tested
- Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy
- Keywords
- Drinking, Alcohol problems, Alcoholism, Gay men, Bisexual men, Moderation-oriented treatment, Controlled drinking, Non-abstinence based treatment
- Medical subject headings
- Alcohol-Related Disorders, Alcohol Drinking, Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NaltrexoneDrug
Also called Naloxone, Revia, Depade
Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
Modified Behavioral Self-Control PsychotherapyBehavioural
Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
Brief Behavioral Compliance Enhancement TherapyBehavioural
Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy Receives: Drug: Naltrexone; Behavioral: Modified Behavioral Self-Control Psychotherapy; Behavioral: Brief Behavioral Compliance Enhancement Therapy |
| 2 | Experimental | Placebo combined with Modified Behavioral Self-Control Psychotherapy Receives: Behavioral: Modified Behavioral Self-Control Psychotherapy; Behavioral: Brief Behavioral Compliance Enhancement Therapy |
| 3 | Experimental | Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy Receives: Drug: Naltrexone; Behavioral: Brief Behavioral Compliance Enhancement Therapy |
| 4 | Placebo comparator | Placebo + Brief Behavioral Compliance Enhancement Therapy Receives: Behavioral: Brief Behavioral Compliance Enhancement Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantity of alcohol use
Measured: 9 months
Frequency of binge drinking
Measured: 9 months
Secondary outcomes (1)
Frequency of HIV risk behavior
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2007 (estimated)
- Study startApr 2006
- Primary completionFeb 2010
- Study completionJun 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol-related DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Principal investigator, Alexis Kuerbis, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Investigators
- Jon Morgenstern, PhD, Principal investigator, Columbia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00444418
- Sponsor's protocol ID
- NIAAAMOR_015553-01A1S1
- Other IDs
- NIH Grant AA015553-01A1S1
- Status last verified
- Apr 2013
- First submitted
- 6 Mar 2007
- Last updated
- 1 May 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Naltrexone and CBT for Problem-drinking MSM
- ClinicalTrials.gov ID
- NCT00444418
- Acronym / sponsor ID
- NIAAAMOR_015553-01A1S1
- Conditions
- Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
- Keywords
- Drinking, Alcohol problems, Alcoholism, Gay men, Bisexual men, Moderation-oriented treatment, Controlled drinking, Non-abstinence based treatment
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)US National Institutes of Health
- Study start
- Apr 2006
- Primary completion
- Feb 2010 (actual)
- Study completion
- Jun 2010 (actual)
- First posted
- 7 Mar 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to study the effectiveness of medication and specialized psychotherapy in helping gay and bisexual men who do not want to quit drinking learn how to reduce their drinking to healthier levels. More information on the study is available at www.projectsmartnyc.org.
Detailed description
Problem drinking gay and bisexual men who try to quit drinking are at risk for relapse to heavy or problematic drinking because their social lives and social outlets are often strongly associated with alcohol. These men are most receptive to interventions focused on moderation of drinking rather than abstinence. However moderation-oriented cognitive-behavior therapy (CBT) and naltrexone (NTX) are both well established treatments for problem drinkers who wish to moderate, rather than stop, drinking. Research suggests that combining these treatments may enhance their efficacy.
This study combines moderation-oriented CBT with NTX in the treatment of problem drinking gay and bisexual men, who do not wish to abstain from alcohol, to evaluate their efficacy alone and in combination. We also propose to utilize new data collection technology, Interactive Voice Response, to collect data on daily relations among drinking, sexual behavior and psychological variables thought to mediate treatment response. Our objectives are to evaluate the efficacy of 12 weeks of randomly assigned treatment, with 100 mg of NTX or placebo, combined with brief supportive therapy or modified, behavioral self-control therapy specifically tailored to gay/bisexual men; to evaluate conditional relationships between heavy drinking and likelihood of HIV risk behavior; and to evaluate daily associations among mood, craving, self-efficacy, motivation, and drinking. Assessments will include baseline, 3, 6, \& 9 month follow-up. A substudy of the treatment trial will be conducted to collect and bank samples from blood for research aimed at associating naturally occurring differences in DNA with patient response to NTX, and with potential mediational mechanisms of action of NTX. Information gathered on genes or gene products may be used in conjunction with data on clinical and psychological factors obtained as part of the clinical trial to evaluate relationships among genetic variants, drug effects, and mechanisms of treatment response. Patients will be asked to give a blood sample at Week 0 of the clinical trial for the purpose of carrying out genetic research.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Naltrexone, Behavioral: Modified Behavioral Self-Control Psychotherapy, Behavioral: Brief Behavioral Compliance Enhancement TherapyActive medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy |
| 2 | Experimental | Behavioral: Modified Behavioral Self-Control Psychotherapy, Behavioral: Brief Behavioral Compliance Enhancement TherapyPlacebo combined with Modified Behavioral Self-Control Psychotherapy |
| 3 | Experimental | Drug: Naltrexone, Behavioral: Brief Behavioral Compliance Enhancement TherapyActive medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy |
| 4 | Placebo comparator | Behavioral: Brief Behavioral Compliance Enhancement TherapyPlacebo + Brief Behavioral Compliance Enhancement Therapy |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Males 18-65 years old
- Currently sexually active with other men
- Report drinking at levels substantially in excess of established guidelines for non-hazardous drinking
- Willing to reduce drinking to non-hazardous levels
- English literate (8th grade level)
Key exclusion criteria (9 listed)
- Current physical disease or condition making participant inappropriate for a medication trial, including total bilirubin elevation >110%, AST or ALT elevations >300%.
- History of serious psychiatric illness (psychotic disorder, bipolar disorder, or psychiatric illness requiring hospitalization), current psychiatric illness (such as major depression or post-traumatic stress disorder) that requires treatment but that is currently untreated, or serious risk of suicidal or violent behavior
- Recent (past three months) initiation of psychotropic medication or psychotherapy, or recent change in psychotropic medication treatment
- Current DSM-IV diagnosis of drug (other than nicotine) dependence, or lifetime diagnosis of opioid dependence
- DSM-IV alcohol dependence diagnosis judged clinically severe, history or present evidence of significant alcohol withdrawal symptoms, or recurrent use of alcohol to alleviate withdrawal
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NaltrexoneAlso: Naloxone, Revia, DepadeNaltrexone, 100 mg. oral dosage, daily for 12 weeks. | Drug | 1, 3 |
| Modified Behavioral Self-Control PsychotherapyModeration- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions. | Behavioural | 1, 2 |
| Brief Behavioral Compliance Enhancement TherapyBrief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption | Behavioural | 1, 2, 3, 4 |
Primary outcome
Quantity of alcohol use
Time frame: 9 months
Frequency of binge drinking
Time frame: 9 months
1 secondary outcome
Frequency of HIV risk behavior
Time frame: 9 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2013.
Related trials for Alcohol-related Disorders
Not yet recruitingEarly Phase 1
Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder
Opioid Use Disorder, Alcohol Intoxication
RecruitingPhase 1
Spironolactone in Alcohol Use Disorder (SAUD)
Alcohol Use Disorder
Recruiting
MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education
Alcohol Use, Cannabis Use
Active, not recruiting
Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People
Substance Use Disorders, HIV Infections
Recruiting
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
Alcohol Abuse, Alcohol Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jon Morgenstern, PhD principal investigator
Columbia University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Naltrexone and Brief Behavioral Compliance Enhancement Therapy in people with Alcohol-related Disorders and Alcohol Drinking, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 May 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantity of alcohol use (time frame: 9 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2013.